Of these, the most frequent mutations are found in PIK3CA and PTEN. In preclinical BC models, activating mutations in PIK3CA correlate with sensitivity to PI3Kα and AKT inhibitors, while loss-of-function mutations in PTEN are associated with increased sensitivity to PI3Kβ and AKT inhibitors [4–8]. This evidence concerns the gene PTEN and breast cancer.